Registry for patients with chronic lymphocytic leukemia and related conditions
Registry of the German CLL Study Group Long Term Follow-up of Patients With CLL, B-PLL, T-PLL, SLL,T or NK-LGL, HCL and Richter's Transformation
This study is tracking patients with chronic lymphocytic leukemia and similar conditions to see how well different treatments work and what long-term effects they might have.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 8000 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | German CLL Study Group Academic / other |
| Drugs / interventions | rituximab, chemotherapy, Cyclophosphamide, Fludarabine |
| Locations | 1 site (Dresden, Saxony) |
| Trial ID | NCT02863692 on ClinicalTrials.gov |
What this trial studies
This observational registry focuses on the long-term follow-up of patients diagnosed with chronic lymphocytic leukemia (CLL) and related conditions such as B-prolymphocytic leukemia, T-cell prolymphocytic leukemia, and others. The study aims to assess overall survival and progression-free survival, while also evaluating late toxicities associated with various treatments. By collecting extensive clinical data, the registry seeks to analyze the outcomes of different therapies and their long-term effects on patients. This comprehensive approach will help in understanding the disease better and improving future treatment strategies.
Who should consider this trial
Good fit: Ideal candidates include adults aged 18 and older with a confirmed diagnosis of CLL, B-PLL, T-PLL, SLL, T or NK-LGL, HCL, or Richter's transformation.
Not a fit: Patients without a confirmed diagnosis of the specified leukemias or those with cerebral dysfunction may not benefit from this registry.
Why it matters
Potential benefit: If successful, this registry could provide valuable insights into the long-term outcomes and treatment effects for patients with CLL and related leukemias.
How similar studies have performed: Other studies have shown success in similar observational approaches, indicating the potential for valuable findings in this area.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria (all must apply) 1. Confirmed diagnosis of CLL, B-PLL, T-PLL, SLL, T or NK-LGL, HCL or Richter's transformation 2. 18 years of age or older 3. Signed, written informed consent 4. Presence of one or more of the following disease situations: * Newly diagnosed patients without treatment indication (eligible for watch and wait Approach Treatment within a clinical trial according to the AMG or status post participation in a clinical Trial) * Treatment with standard therapies approved for the eligible entities or status post treatment (outside of clinical trials) * Referral for evaluation the indication for HSCT * Relapsed disease status (even if first diagnosis was prior to activation of the registry) Exclusion Criteria 1. Patients without confirmed diagnosis of CLL, B-PLL, T-PLL, SLL, T or NK- LGL, HCL or Richter's transformation 2. Cerebral dysfunction, legal incapacity
Where this trial is running
Dresden, Saxony
- BAG Freiberg-Richter, Jacobasch, Wolf, Illmer — Dresden, Saxony, Germany (Recruiting)
Study contacts
- Study coordinator: Anna-Maria Fink, MD
- Email: cllstudie@uk-koeln.de
- Phone: +4922147888220
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.